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Abstract Background Controversy about the introduction
of a non-dispensing pharmacist in primary care practice
hampers implementation. Objective The aim of this study is
to systematically map the debate on this new role for phar-
macists amongst all stakeholders to uncover and understand
the controversy and consensus. Setting: Primary health care
in the Netherlands. Method Qmethodology. 163 participants
rank-ordered statements on issues concerning the integration
of a non-dispensing pharmacist in primary care practice.
Main outcomemeasure: Stakeholder perspectives on the role
of the non-dispensing pharmacist and pharmaceutical care in
primary care. Results This study identified the consensus on
various features of the non-dispensing pharmacist role aswell
as the financial, organisational and collaborative aspects of
integrating a non-dispensing pharmacist in primary care
practice. Q factor analysis revealed four perspectives: ‘‘the
independent community pharmacist’’, ‘‘the independent
clinical pharmacist’’, ‘‘the dependent clinical pharmacist’’
and ‘‘the medication therapy management specialist’’. These
four perspectives show controversies to do with the level of
professional independency of the non-dispensing pharmacist
and the level of innovation of task performance. Conclusion
Despite the fact that introducing new professional roles in
healthcare can lead to controversy, the results of this Q study
show the potential of a non-dispensing pharmacist as a
pharmaceutical care provider and the willingness for inter-
professional collaboration. The results from the POINT
intervention study in the Netherlands will be an important
next step in resolving current controversies.
Keywords Clinical pharmacist  General practitioner 
Integrated care  Netherlands  Primary care  Q method
Impact on practice
• Most primary care professionals recognize the need for
more integration of pharmaceutical care into daily
primary care practice.
• General practitioners and community pharmacists
regard the introduction of the non-dispensing pharma-
cist as a possible route to integrate pharmaceutical care
into practice.
• Most primary care professionals agree that the non-
dispensing pharmacist should be an integral part of the
primary care team, offering consultations to vulnerable
patients with polypharmacy.
• Although further separation of pharmaceutical care and
drug dispensing is considered as the key paradigm shift,
there is discussion about the best way to implement this.
Introduction
Co-locating a non-dispensing pharmacist (NDP) in primary
care practice, including shared use of patients’ medical
records, is expected to improve interprofessional
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collaboration and communication and thus effective
patient-centred medication management services [1].
However, controversy about this new role for pharmacists
is hampering implementation. Different perceptions have
led to significant barriers preventing pharmacists from
expanding their roles as pharmaceutical care providers. The
barriers include lack of mandate, legitimacy, effectiveness
and readiness to embrace change [2]. Currently, NDPs have
been integrated successfully in primary care practice in
only a limited number of health care settings, mainly in
Great Britain, the United States, and Canada [3–5].
Interprofessionality is an essential feature of healthcare
development [6], reflected in the willingness to work in
interprofessional teams [7]. Yet, introducing new roles in
healthcare practices puts professional boundaries under
pressure [8]. New roles lead to the substitution of labour,
including reallocation of resources and control. Conse-
quently, it has an impact on dominance and authority, fed by
the implicit wish to maintain established arrangements for
healthcare delivery and by scepticism about the feasibility
and effectiveness of related professionals working jointly [6].
Despite the identified positive attitude to team-based
work, attempts to introduce the NDP to primary care
practice have led to debate, as evidenced by several qual-
itative studies on stakeholder experiences with NDPs in
primary care practices [9, 10].
Aim of the study
In this Q-study we systematically map the debate on the
introduction of NDPs in primary care practice amongst all
involved stakeholders to uncover and understand the con-
troversy and consensus.
Ethics approval
This Q study is part of the POINT project, which aims to
evaluate the effect of integration of an NDP in general
practice with regard to the quality and safety of pharma-
cotherapy [11]. This project is exempted of formal medi-
cal-ethical approval by the Medical Ethical Committee
University Medical Centre Utrecht (METC protocol num-
ber 13-432C).
Method
Research design
Q methodology [12] was used to disclose different view-
points on the value and position of the NDP in primary
healthcare. The Q method is a robust and hybrid qualita-
tive–quantitative technique that provides a basis for the
systematic study of subjectivity and accentuates shared
understanding [13]. A Q study consists of three steps:
construction of the Q set, performing Q sorting and anal-
ysis of obtained data [14, 15].
Step 1 Constructing the Q set.
The first step is the collection of statements broadly
covering the debate on the subject at hand. In Q method-
ological terms this is called ‘‘the concourse’’ [14, 15]. The
concourse on integration of an NDP in primary care was
based on the literature and collected from six interviews
with pharmaceutical and medical experts. From this con-
course we drew a subset of 116 statements. Since careful
consideration of the context is helpful to a better under-
standing of the debate on NDP integration, we deliberately
added a number of general statements on improving
pharmaceutical care in primary care. The subset of 116
statements was stripped of double and comparable state-
ments and condensed to a Q set of 37 statements (Table 1).
The statements were evaluated by a group of experts who
were both pharmacists, general practitioners (GP) and
researchers with experience in Q methodological studies.
They refined the statement set to improve readability and
clarity. Next, statements were assessed and sorted by a
small group of general practitioners and pharmacists.
Finally, statements were again refined and improved. The
result was the final Q set which was considered represen-
tative for the issues raised on integrating an NDP in pri-
mary care. Quoted statements were originally phrased in
Dutch.
Step 2 Performing Q sorting.
For Q sorting, respondents considered to have a clear
and distinct viewpoint were selected. In this study, they
were community, clinical and hospital pharmacists and
GPs with varying levels of work experience, located in
both rural and urban settings; other pharmaceutical and
medical experts; health care insurers; policy makers;
practice nurses and patients. Members of the research team
approached a convenience sample of respondents for Q
sorting online or in person. Q sorting in personal interviews
was done by two researchers (AH and AW). Q sorting
started by sorting the 37 statements into three categories:
‘agree,’ ‘neutral’ or ‘disagree.’ Next, respondents were
asked to place the statements in a Q sorting table (Fig. 1).
Respondents were requested to adhere to the Q sorting
table, in order to gradually force them to take position on
the statements. Q methodology combines statement-sorting
and interviews to unravel different perspectives. Therefore,
respondents were asked to comment on the four statements
at the extreme ends (-3 being disagree most and ?3 being
agree most). FlashQ was used as an online Q sorting
programme [16].
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Step 3 Analysis of obtained data.
The final step in Q methodology is by-person factor
analysis in order to identify significant correlation between
individuals, expressed as factors with common viewpoints
and preferences [14]. In this study, obtained Q sorts were
analysed using PQMethod 2.35 [17]. By-person factor
analysis with centroid factor extraction and varimax rota-
tion was conducted with the aim to obtain a clear pattern of
relationships between the factors [15]. Since more than the
theoretically required minimum of 40–60 respondents was
included, it was decided to increase significance [15, 18].
As a result, Q sorts that loaded significantly on one factor
(with p\ 0.01) were included in the analysis. For each
factor solution an idealized Q sort was computed. This
idealized Q sort represents how a person with a 100 %
loading on that factor would have ranked the 37 statements
[14, 15].
The content of the factors was examined by reviewing
the characterising, distinguishing and consensus state-
ments. Characterising statements are the statements that a
factor most (rating ?2 or ?3) or least (rating -2 or -3)
agrees with. The characterising statements are a first peek
into the content of a factor. Distinguishing statements are
the statements on which factors have different opinions.
These statements highlight the differences between fac-
tors. Consensus statements are the statements with which
all factors (dis)agree. These statements uncover the
common viewpoints between factors [14, 15]. Statistical
characteristics of the different factor solutions were
evaluated.
Results
A total of 163 participants performed Q sorting: 125 online
(77 %) and 38 in person (23 %). Respondents had an
average of 17 years of work experience in healthcare
(Table 2). Q analysis of the Q sorts supported a maximum
of five factors. Content and statistical characteristics were
examined for three-, four- and five-factor solutions. The
four-factor solution was selected as the desirable solution,
based on statistical characteristics, defining statements and
written and verbal comments provided by the respondents
defining the factors during Q sorting. These four factors
explained 53 % of the total variance in the Q sorts
(Table 3).
The next section presents quotations of comments made
by respondents (italics). The figures in parentheses, pre-
ceded by ‘‘s’’, correspond to statement numbers in Table 1.
Similarities between factors
All participants shared the same opinion of many state-
ments (Fig. 2).
First, all participants in either factor A, B, C or D
believe that an NDP improves adherence (s6), should focus
on individual patient care (s18) and does not take over too
many tasks of the GP (s37). Second, it is thought evident
that the work of an NDP could not be done by a practice
nurse (s29). According to some respondents, the pharma-
ceutical knowledge of the practice nurse is ‘‘nowhere near
as extensive as the NDP’s.’’ However, some participants
Fig. 1 Q sorting table
1254 Int J Clin Pharm (2016) 38:1250–1260
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suggested that the practice nurse could support the NDPs in
the follow-up of some care issues.
Third, all factors emphasize that health insurance com-
panies pay too little for pharmaceutical care (s8) and that
there should be funding earmarked for pharmaceutical care
(s10): ‘‘Pharmaceutical care is variable and hard to
quantify. So it’s challenging for health insurance compa-
nies to develop a good reimbursement system.’’ This leads
to ‘‘low quality patient consultations and medication
reviews.’’ And ‘‘since reimbursement is insufficient, eval-
uation and follow-up are neglected. Also, quality projects
are initiated, but not embedded.’’
Fourth, access to medical records is thought a prereq-
uisite for pharmaceutical care (s20). Numerous participants
commented that especially knowledge of (contra-)indica-
tions and the results of lab tests are important in providing
safe pharmaceutical care. Respondents also stressed the
importance of access to medical data: ‘‘Without access to
medical records it’s impossible to properly assess the
quality of pharmacotherapy and to develop a pharmaceu-
tical care plan tailored to the needs of individual patients.’’
Fifth, another organisational aspect which all factors
agree with unanimously is that NDP integration does not
pose a risk to patient safety, despite it creating an addi-
tional link between prescription and delivery (s3).
Finally, clearly GP and NDP share a common goal in the
pharmacotherapy of the patient (s21): ‘‘[Providing good
patient care] is indisputable. […] Everything else (costs,
practical implementation etc.) is secondary.’’ Moreover, all
Table 2 Baseline
characteristics participants
Characteristic Number
Total number of respondents 163
Female 50 % (n = 82)
Age, mean (range) 45 years (24–77)
Total years of experience in healthcare, mean (range) 17 years (0–42)
Medical and/or pharmaceutical positions Percentage (n)
Pharmacy 28 % (60)
Community pharmacist 18 % (37)
Non-dispensing pharmacist 4 % (9)
Hospital pharmacist 3 % (7)
Pharmacist trainee 3 % (7)
General practice 16 % (35)
General practitioner 11 % (24)
General practitioner trainee 3 % (7)
Practice nurse 2 % (4)
Other medical and/or pharmaceutical expert 34 % (71)
University teacher or professor 49 % (35)
Medical advisor 17 % (12)
Medical doctor (no GP) 14 % (10)
Researcher 8 % (6)
Employee research and medication safety institute 7 % (5)
Employee health insurance company 4 % (3)
Policy maker 13 % (28)
Pharmacy or medical student 5 % (11)
Patient 2 % (5)
Some participants fulfil multiple positions (e.g. a part-time GP also working part-time as policy maker). As
a result 163 participants fulfil 211 positions
Table 3 Factor characteristics
Characteristic Factor
A B C D
Number of defining variables 27 50 20 8
Explained variance (%) 15 18 11 9
Cumulative (%) 33 44 53
Correlation between factors
B 0.59
C 0.68 0.46
D 0.68 0.55 0.69
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respondents agree that pharmaceutical care would be
improved by shared training in GP and pharmacist educa-
tional programmes (s16).
Differences between factors
Despite the large number of statements on which all par-
ticipants shared the same opinion, controversies between
the four factors are identified (Fig. 2).
Factor A: ‘‘independent clinical pharmacist’’
Participants aligned with factor A, one-third of whom were
medical or pharmaceutical experts (Table 4), seem to fully
support NDP integration in general practice. Working in
the same organisation is considered necessary to enable
successful collaboration between GP and NDP (s28). ‘‘The
GP and NDP will share the same vision and principles
when they work in one organisation. Integrating an NDP
Fig. 2 The four factors covering the debate on NDP integration in general practice
Table 4 Defining participants
Expertise Factor A (n = 27) Factor B (n = 50) Factor C (n = 20) Factor D (n = 8)
Percentage (n) Percentage (n) Percentage (n) Percentage (n)
Community pharmacist 11 (3) 44 (22)
Non-dispensing pharmacist 19 (5) 2 (1)
Hospital pharmacist 7 (2) 2 (1) 25 (n = 2)
Pharmacist trainee 12 (6)
General practitioner 4 (1) 4 (2) 45 (9) 25 (n = 2)
General practitioner trainee 4 (1) 20 (4)
Practice nurse 4 (1) 5 (1)
Other medical and/or pharmaceutical expert 33 (9) 18 (9) 20 (4) 25 (n = 2)
Policy maker 7 (2) 8 (4) 25 (n = 2)
Pharmacy or medical student 11 (3) 10 (5) 5 (1)
Patient 5 (1)
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stimulates close collaboration and this will result in
unambiguous pharmaceutical care for the patient.’’ Since
the community pharmacist is not fully informed of the
details of the pharmacotherapy of the individual patient
(s5), an NDP can provide better pharmaceutical care.
Specifically the knowledge about clinical pharmacology
that an NDP brings into general practice is regarded as
added value (s15). When it comes to complicated patients,
the importance of the knowledge of the NDP in primary
care is emphasised:
‘‘The unique combination of an NDP’s knowledge of
medication and clinical experience enables him to tailor
the pharmacotherapy to the needs of the individual patient.
This is particularly important with multimorbidity and
polypharmacy, when patients really can’t be treated
according to the guideline for one specific disease or
condition.’’
Introducing a new care provider in general practice
might confuse patients as to whom they should address
questions related to medication (s1). Nevertheless, factor A
does not identify this as a problem: ‘‘When a clinical
pharmacist takes care of a patient, they establish a rela-
tionship which makes it natural for the patient to consult
them about their pharmaceutical care issues.’’ Participants
disagree with the statement that an NDP loses their inde-
pendent position as healthcare provider as an employee of a
general practice (s11): ‘‘The clinical pharmacist’s profes-
sional integrity will not be influenced by the organisational
framework of the workplace.’’ ‘‘An NDP has its own
expertise and independency.’’ However, participants com-
mented that it will take some time to adjust to this new role
of a pharmacist. Respondents loading on this factor dis-
agree with the statement that the NDP takes on too many
tasks of the GP (s37). ‘‘The NDP doesn’t take over too
much of the pharmaceutical care, but enhances it by
working together with the GP.’’
Participants of factor A show confidence in a nationwide
introduction of this new pharmacists’ role. This is underlined
by the statement thatNDP introductionwill notmake primary
care unnecessarily expensive (s12): ‘‘Healthcare costs might
be reduced by preventing adverse effects, overprescribing
and medication-related hospital admissions.’’
Factor B: ‘‘independent community pharmacist’’
Participants aligned with factor B, over forty percent of
whom were community pharmacists (Table 4), insist that
the community pharmacist should be the leading indepen-
dent pharmaceutical care provider, with sufficient financial
reimbursement as a prerequisite to perform this role. The
participants agree with the statement that a fee for practice
costs is necessary to deliver pharmaceutical care (s9):
‘‘Improper reimbursement for pharmaceutical care results
in hasty dispensing [pharmaceutical activities performed in
a short amount of time] resulting in low quality pharma-
ceutical care and inadequate follow-up.’’ The participants
aligning with this factor disagree that a community phar-
macists is unable to perform pharmaceutical care. This is
reflected by their disagreement on: the community phar-
macist is insufficiently informed about the patients’ indi-
vidual pharmacotherapy (s5) and the community
pharmacist is not skilled to perform patient consultation
(s27). They said, ‘‘patient consultation is the most impor-
tant part of our job’’ and ‘‘during our training, and in the
community pharmacy, it’s crucial to have good communi-
cation skills otherwise you can’t do your job as a (com-
munity) pharmacist.’’
These participants share the opinion that a community
pharmacist should advise on the choice of medication
(s17): ‘‘Nowadays medication is an important part of
therapy. The [up-to-date] pharmaceutical knowledge of a
community pharmacist is more extensive than the GP’s
knowledge. A community pharmacist can, with this
knowledge, increase adherence, efficiency and medication
safety by giving advice on the choice of medication.’’
Moreover, these participants disagree with the statement
that the patient has more confidence in the NDP than in the
community pharmacist (s4). They strongly disagree with
the statement that pharmaceutical care can best be
accommodated at a general practice (s32) and that clinical
medication reviews should take place in the GP practice
(s19): ‘‘Medication reviews can also take place in com-
munity pharmacy. It’s not really a matter of where the
reviews are done, what’s important is that they are done.
Medication reviews should be done in collaboration with
the prescriber and the patient.’’ Therefore, an NDP can
also be stationed at a community pharmacy; a potential
conflict of interest, due to both consulting on medication
and selling it is thought unlikely (s36). Dissimilar to the
other factors (A, C and D), participants of factor B strongly
support linking dispensing medication and both patient
education and giving advice on pharmacotherapy (s31,
s26). These statements illustrate the wish to keep general
practice and community pharmacy separate. ‘‘Dispensing
medication involves more than a GP can handle. GPs have
only a limited amount of time per patient. They have little
time to give advice on medication, let alone take care of the
dispensing.’’
Factor C: ‘‘dependent clinical pharmacist’’
The theme of this factor is pharmaceutical care improve-
ment, managed primarily by GPs, with a supporting role
for the NDP to join the team as a dependent pharmaceutical
care provider. Sixty-five percent of the participants defin-
ing this factor were GPs or GP trainees (Table 4).
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Unlike the other factors (A, B and D), participants in
factor C believe that the GP has enough knowledge of
medication (s13): ‘‘In general, no major accidents happen
due to the GP’s pharmacotherapeutic choices. Over the
past years, the GP’s knowledge has increased.’’ However,
GPs are considered to be open to having more healthcare
providers in their practice and encourage multidisciplinary
teamwork (s2): ‘‘The support from other caregivers is very
nice, since a doctor can’t know it all.’’ In line with this
multidisciplinary approach, participants aligning with this
factor are open to having an NDP in their practice and
debate the statement that a pharmacist has an inferior
position which could impede medication safety (s23): ‘‘A
pharmacist is not inferior. Collaborating on conducting
safe practice together is the main issue.’’ Medication safety
is not thought endangered by inequality in positions but ‘‘a
lack of collaboration or organisational flaws’’ are consid-
ered the most likely cause of medication safety problems.
Those aligning with this factor are the only respondents
who agree with the statement that an NDP cannot be
employed at a community pharmacy due to a conflict of
interest (s36). They agree with the statement that the
patient has more confidence in the NDP than in the com-
munity pharmacist (s4): ‘‘Patients associate general
practice with good quality of care. They prefer to discuss
their care issues with healthcare providers who are phys-
ically present in general practice.’’ Therefore, clinical
medication reviews should be organised in general practice
(s19): ‘‘The GP is the centre point of primary care. That’s
why it’s logical to do medication reviews in general
practice’’ and ‘‘the access to medical records in general
practice facilitates medication reviews.’’ Pharmaceutical
care provision can be performed in close collaboration with
an NDP but in contrast to the respondents aligning with
factors A and B, respondents on factor C disagree with the
statement that an NDP should be an independent prescriber
(s34): ‘‘A pharmacist is not a medical doctor.’’
Factor D: ‘‘medication therapy management specialiste-’’
Factor D supports the idea of integrating an NDP in primary
care and shows similarities with factors A and C, although
this vision of the added value of an NDP includes managerial
expertise. Also, this factor shows somemistrust in the ability
of community pharmacists to provide good pharmaceutical
care. Participants defining this factor are a heterogeneous
group of GPs, hospital pharmacists, policy makers and other
medical and/or pharmaceutical experts (Table 4).
The added value of an NDP is made tangible by their
proactive task to screen patients with potential drug therapy
problems (s25): ‘‘An NDP can intervene before medicines
are prescribed, while intervening afterwards is inconve-
nient, time-consuming and confuses the patient.’’ A GP
who worked with an NDP stated: ‘‘In our practice, the
NDP’s particular expertise to proactively identify high risk
patients resulted in improved patient safety.’’ Besides this
preventive approach, factor D is most outspoken about the
individual patient care an NDP should deliver (s18). Also,
they are most distinct about the NDP not being an inde-
pendent prescriber (s34): ‘‘Prescribing and monitoring
medication have to be separate at all times’’ and ‘‘the GP
will lose control over patient care if multiple healthcare
professionals are allowed to prescribe medication inde-
pendently’’ and ‘‘the pharmacist has not enough (clinical)
knowledge about a patient.’’ Despite the latter, the GP
conceded their insufficient knowledge of medication (s13):
‘‘GPs get very little schooling on medication.’’
This factor suggests that educating patients on their
pharmacotherapy can be separated from dispensing medi-
cation (s31). Moreover, it was stated that the information
on medication given by the community pharmacist to the
patient does not reflect the GP’s advice well enough (s22):
‘‘Unfortunately, patients are often confused by the different
advice in the community pharmacy.’’ Also, participants
aligning with this factor disagree on the statement that a fee
for practice costs for community pharmacists is essential to
enable delivery of pharmaceutical care (s9). This implies
that this factor does not necessarily support the develop-
ment of community pharmacists as pharmaceutical care
providers. On the other hand, participants aligning with
factor D acknowledge that a community pharmacists’ pri-
mary concern is not the financial status of the pharmacy
business (s7), which suggests the possibility of another
primary concern, for instance pharmaceutical care.
Discussion
We systematically mapped the debate amongst stakehold-
ers on introducing an NDP in primary care practice and
revealed four perspectives: ‘‘the independent community
pharmacist’’ (Factor B), ‘‘the independent clinical phar-
macist’’ (Factor A), ‘‘the dependent clinical pharmacist’’
(Factor C) and ‘‘the medication therapy management spe-
cialist’’ (Factor D).
Factors A, C and D favour NDP integration in primary
care practice. The main contrast between factors A and C
concerns the level of professional independence, which is
an eminent point of debate when introducing new roles into
current practice. Fournier says that the construction of
boundaries and the creation of an independent area of
knowledge is crucial to professional development [19]. In
accordance with this, factor A supports the integration of
an NDP as an ‘‘independent clinical pharmacist’’ based
upon the clinical knowledge that an NDP brings into
practice and the benefits of working within the same
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organisation. This creates interprofessional trusting rela-
tionships and integrates work processes, thereby improving
quality and continuity of individual patient care. Despite
the restricted clinical, economic and political autonomy of
pharmacists described by Edmunds [20], factor A high-
lights development in the process of reprofessionalisation
of pharmacy.
In contrast to factor A, factor C stresses the role of an
NDP in general practice as a ‘‘dependent clinical pharma-
cist’’ within a multidisciplinary team of healthcare pro-
fessionals, with drug monitoring and not drug prescription
as the primary task. This perspective accentuates the GPs’
wish to maintain professional dominance, triggered by
external threats of their privileged position [8]. Also, it is
acknowledged that GPs are hesitant about the clinical roles
of medication management performed by community
pharmacists [2]. This hesitance towards community phar-
macists might have influenced their perception of the level
of independence that an NDP in primary care practice
should attain.
Factor D is distinct about the innovation level of tasks
performed by NDPs. Supporters of this factor promote a
new model of care: an NDP as a ‘‘medication therapy
management specialist’’ who focuses on proactive screen-
ing (and treating) of patients with potential drug therapy
problems, thereby integrating managerial expertise and
values into the professional work. It involves population-
focused preventive care, which is important in an era with a
large ageing population, to prevent avoidable chronic dis-
eases and unnecessary medical expense [21].
While factors A, C and D favour NDP integration in
primary care practice, factor B see pharmaceutical care
provision improved by maintaining and expanding the
traditional roles of community pharmacists. The respon-
dents aligning with factor B underline the essential role of
community pharmacists as leading pharmaceutical care
providers [22]. According to the respondents of factor B,
pharmaceutical care, including dispensing medication,
should definitely not be accommodated in general practice.
Factor B wishes to enhance the level of independence of
community pharmacists in the context of treating individ-
ual patients to legitimate their role as pharmaceutical care
professionals [20]. They see clear boundaries and the cre-
ation of an independent area of knowledge crucial to the
professional development of the pharmacist [19].
Although these four perspectives are distinct, we iden-
tified a relatively large overlap between them. There was
consensus on the potential of the NDP as a pharmaceutical
care provider. Moreover, all respondents in this Q study
were consistent in their view on financial, organisational
and collaborative issues such as more funding for phar-
maceutical care improvements, better access to medical
records for pharmacists, shared education for GPs and
pharmacists, and shared responsibility for the outcome of
pharmacotherapy. This high level of consensus demon-
strates a willingness for interprofessional collaboration and
a positive attitude towards different aspects of an NDP
integrated in primary care practice.
A strength of this study is that it included participants
with a large variety of medical and pharmaceutical expe-
rience. This makes it likely that it represents all the dif-
ferent viewpoints on the NDP in Dutch general practice.
No indications for missing topics were found in the eval-
uation by the expert group and pilot study. Also, this study
is part of the POINT study, a large multicenter intervention
study on NDPs in Dutch primary care practice [11] and the
results of this Q study will contribute to further develop-
ment of the intervention.
This study does have limitations. Firstly, nothing can be
said about the prevalence of the four factors amongst
pharmacists, GPs and external stakeholders in the wider
population since Q methodology is not designed for this
purpose. Secondly, for pragmatic reasons the majority of
the respondents ranked the Q set electronically, including
computer-based interviews instead of personal interviews.
In-person interviews enable the researcher to better
understand and interpret the results. However, we identified
no apparent differences in reliability or validity of these
two methods of administration [23].
Since all stakeholders underline the potential benefit of
an NDP as pharmaceutical care provider, we need to reflect
upon the financial aspects of these services. As said, all
stakeholders agree that more and earmarked funding is
needed to improve pharmaceutical care. In the POINT
study that we are currently evaluating, the NDP services
were funded via a temporary grant [11]. A sustainable
model of reimbursement for the services performed by
NDPs is needed. The employer could than either be com-
munity pharmacies or GP practices. A community phar-
macy fee finance model, however, is less feasible because
this model is based on dispensing of medication. The rel-
atively small fees for pharmaceutical services obstruct
employment of an NDP in community pharmacies.
Implementation through the GP fee finance model is fea-
sible, but limited to groups of collaborating GP practices.
Implementation of the NDP would probably be optimal if
dedicated additional funding from the insurance company.
Whether and how an NDP can be employed in other health
care systems heavily depends on the local situation. Hence,
it would be relevant to replicate this study in a country with
a different health care system.
It is important to define the scope of practice of NDPs in
comparison to both the community and clinical pharma-
cists. The NDP is the clinical pharmacist in primary care.
While earlier initiatives to bring hospital clinical pharma-
cists in primary care failed, the NDP provides an
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alternative role. NDP services will add especially to the
quality of pharmaceutical care of specific subgroups of
individual patients, such as elderly patients and those with
polypharmacy. The community pharmacist will—in addi-
tion to dispensing medication and medication surveil-
lance—provide pharmaceutical care connected to the
pharmaceutical product to less complex patients. In con-
trast to the UK and the US, neither community pharma-
cists, clinical pharmacists nor NDPs can prescribe drugs in
the Netherlands. In the current study prescribing by phar-
macists was not seen a priority for an NDP.
Conclusion
Despite the fact that introducing new professional roles in
healthcare can be controversial, this Q study identified a
consensus on various features of the NDP role, as well as on
financial, organisational and collaborative aspects of NDP
integration in primary care practices. This shows the
potential of an NDP as a pharmaceutical care provider and
the willingness for interprofessional collaboration. The
main identified controversies concern the NDP’s level of
professional independence and the level of innovation of
task performance. The results from the POINT intervention
study will be an important next step in resolving current
controversies.
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